AssuredPartners Investment Advisors LLC Has $957,000 Stake in Johnson & Johnson $JNJ

Key Points

• AssuredPartners Investment Advisors LLC reduced its stake in Johnson & Johnson by 41.2%, owning 6,268 shares valued at $957,000 as of its latest SEC filing.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, representing an annualized payout of $5.20 and a dividend yield of 2.7%.
• The stock has shown an increase of 0.6% recently, with a current market capitalization of $465.45 billion and a P/E ratio of 18.65.

AssuredPartners Investment Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 41.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,268 shares of the company's stock after selling 4,390 shares during the period. AssuredPartners Investment Advisors LLC's holdings in Johnson & Johnson were worth $957,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Apexium Financial LP boosted its holdings in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Avanza Fonder AB lifted its position in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC boosted its stake in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.2% in the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock valued at $35,752,000 after buying an additional 2,469 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.6%

JNJ stock opened at $193.27 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The business has a 50-day moving average of $180.49 and a 200-day moving average of $164.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is presently 50.19%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on JNJ shares. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Cowen reiterated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a report on Tuesday, September 16th. Finally, Barclays lifted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $199.59.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.